Oncolytics Biotech Inc (ONCY NASDAQ) stock market data APIs
$0.8504
0.01(1.2%)
as of May 15, 2026
Try our APIs with
free plan!
Oncolytics Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Prev. Close
0.8504
Open
0.8623
High
0.8631
Low
0.8428
52 wk Range
0.3258-1.51
Market Cap
98 709 K
Shares Outstanding
116 M
EPS
-0.01
Beta
1.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncolytics Biotech Inc data using free add-ons & libraries
Get Oncolytics Biotech Inc Fundamental Data
Oncolytics Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -28 655 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-01
- EPS/Forecast: -0.0735
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncolytics Biotech Inc News
New
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tu...
Oncolytics Biotech Reports Data in Colorectal Cancer Study
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to the ...
Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Monday announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration FDA on April 1...
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the la...
Get Oncolytics Biotech Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
